COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period
Turkish Journal of Medical Sciences · 12.12.2023 · 53 (6) · 1744-1755
DOI: 10.55730/1300-0144.5744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 12.12.2023. Verfasst von Gülşen Iskender und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department, of Infectious Diseases and Clinical Microbiology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, …. Hauptthemen laut MEDLINE: COVID-19, Neoplasms, COVID-19 Vaccines, Hospitalization. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/aim:It wasaimed herein to investigate coronavirus disease (COVID-19) in cancer patients and compare hematological and solid organ cancer patients in terms of the course and outcome of this disease. Materials and methods:Data from cancer patients with laboratory-confirmed COVID-19 infection were analyzed retrospectively. Risk factors for poor prognosis and the effect of vaccination on the clinical outcomes of the patients were evaluated. Results:A total of 403 cancer patients who were diagnosed with COVID-19 between March 1st, 2021, and November 30th, 2022, were included, of whom 329 (81.6%) had solid and 74 (18.4%) had hematological cancers. Hospitalization and intensive care unit (ICU) admission rates were significantly higher in the hematological cancer patients compared to the solid organ cancer patients (73.0% vs. 35.9%, p< 0.001 and 25.7% vs. 14.0%, p= 0.013, respectively). The COVID-19-related case fatality rate (CFR) was defined as 15.4%, and it was higher in the hematologicalcancer patientsthan inthe solid organ cancer patients (23.0% vs. 13.7%, p= 0.045) and was higher in patients with metastatic/advanced disease compared to the other cancer stages (p< 0.001). In the solid organ cancergroup, hospitalization, ICU admission, and the COVID-19 CFR were higher in patients with respiratory and genitourinary cancers (p< 0.001). A total of 288 (71.8%) patients had receivedCOVID-19 vaccination; 164 (56.94%) had≤2 doses and 124 (43.06%) had≥3 doses.The hospitalization rate was higher in patients with ≤2 doses of vaccine compared to those with ≥3 doses (48.2% vs. 29.8%,p= 0.002). Patients with COVID-19- related death had higher levels of leucocyte, neutrophil, D-dimer, troponin, C-reactive protein (CRP), procalcitonin, and ferritin and lower levels of lymphocyte than the survivors. In the logistic regression analysis,the risk of COVID-19-related mortality was higher in the hematological cancer patients(OR:1.726), those who were male (OR:1.757), and with the Pre-Delta/Delta variants (OR:1.817). Conclusion:This study revealed that there is an increased risk of COVID-19-related serious events (hospitalization, ICU admission, or death) in patients with hematological cancerscompared with those who have solid organ cancers. It wasalso show cine is more protective against severe illness and the need for hospitalization than ≤2 doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department, of Infectious Diseases and Clinical Microbiology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkiye.
- Department of Infectious Diseases and Clinical microbiology, Ankara Etlik City Hospital, Ankara, Turkiye.
- Division of Medical Oncology, Erzurum City Hospital, Erzurum, Turkiye.
- Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, Ankara, Turkiye.
- Department of Medical Oncology, University of Health Sciences, Ankara, Turkiye.
- Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkiye.
ORCID-Profile: Gülşen Iskender, Duygu Mert, Göknur Yapar Toros, Funda Yilmaz, Ersin Bozan, Semra Tunçbilek, Ömür Berna Çakmak Öksüzoğlu, Fevzi Altuntaş, Mustafa Ertek
Zitieren
APA
Iskender, G., Mert, D., Yapar Toros, G., Yilmaz, F., Bozan, E., Tunçbilek, S., Çakmak Öksüzoğlu, Ö. B., Altuntaş, F., & Ertek, M. (2023). COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. Turkish Journal of Medical Sciences, 53(6), 1744-1755. https://doi.org/10.55730/1300-0144.5744
Vancouver
Iskender G, Mert D, Yapar Toros G, Yilmaz F, Bozan E, Tunçbilek S, et al. COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period. Turkish Journal of Medical Sciences. 2023;53(6):1744-1755. doi:10.55730/1300-0144.5744
BibTeX
@article{Iskender2023,
author = {Iskender, Gülşen and Mert, Duygu and Yapar Toros, Göknur and Yilmaz, Funda and Bozan, Ersin and Tunçbilek, Semra and Çakmak Öksüzoğlu, Ömür Berna and Altuntaş, Fevzi and Ertek, Mustafa},
title = {COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period},
journal = {Turkish Journal of Medical Sciences},
year = {2023},
volume = {53},
number = {6},
pages = {1744--1755},
doi = {10.55730/1300-0144.5744}
}
EUVIMED